HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver

Lédel, Frida; Stenstedt, Kristina; Hallström, Marja; Ragnhammar, Peter; Edler, David

doi:10.3109/0284186x.2014.983654

Cited by 19 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agents targeting EGFR and/or HER2 have been approved for clinical use. In addition, the overexpression or mutation of HER3 is associated with malignant cell growth, contributing to enhanced tumor progression and poor patient outcomes (8). There are potentially oncogenic ERBB4 mutations in non-small cell lung cancer (9), and it has been reported that HER4 is overexpressed in human colon cancer and enhances cellular transformation (10).…”

Section: Introductionmentioning

confidence: 99%

HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer

et al. 2018

View full text Add to dashboard Cite

Abstract. The present study aimed to evaluate the expression of human epidermal growth factor receptor (HER4) isoforms and their ligand neuregulin 1 (NRG1) isoforms in human primary colorectal cancer (CRC). The mRNA expression of HER4 isoforms JM-a, JM-b, CYT1 and CYT2, and their ligand isoforms NRG1 I, II and III in CRC tissues and adjacent normal tissues were quantified by reverse transcription-quantitative polymerase chain reaction analysis. Univariate analysis and logistic regression analysis were performed to analyze the association between HER4 and NRG1 expression and lymph node metastasis in CRC. The expression levels of CYT1 (P=0.002), CYT2 (P=0.002) and NRG1 type III (P<0.001) were significantly higher in the CRC tissues than in the adjacent normal tissues. The expression of CYT2 was correlated with tumor stage (P=0.018), lymph node status (P=0.015) and tumor-node-metastasis (P=0.038) in CRC. The expression of NRG1III was correlated with lymph node metastasis, and the expression of CYT2 was associated with the expression of NRG1III (r=0.691, P<0.01). The logistic regression analysis indicated that expression of CYT2 >50 was a risk factor for lymph node metastasis in CRC. In conclusion the expression levels of CYT1, CYT2 and NRG1III were upregulated in CRC. An expression of CYT-2 >50 was identified as a risk factor for lymph node metastasis in CRC. Therefore, CY-2 and NRG1III may be involved in the progression of CRC.

show abstract

Section: Introductionmentioning

confidence: 99%

HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…To our knowledge, the FIRE-1 trial is the first randomized-controlled trial to investigate the impact of HER2/neu and HER3 receptor overexpression in relation to NRG1 expression and RAS status in mCRC [16][17][18][20][21][22][23][24]. Previous investigations focused mostly on analysing HER2/neu and HER3 expression in advanced colorectal or rectal tumours with patients receiving adjuvant radiotherapy or chemotherapy [17,18,[20][21][22]. The FIRE-1 treatment schedule consisted of 5-FU/LV plus irinotecan or oxaliplatin plus irinotecan as first-line therapy, following a recommended second-line therapy with the respective crossover study regimen.…”

Section: Discussionmentioning

confidence: 99%

“…The FIRE-1 treatment schedule consisted of 5-FU/LV plus irinotecan or oxaliplatin plus irinotecan as first-line therapy, following a recommended second-line therapy with the respective crossover study regimen. With 208 patients enrolled in the analysis, our trial represents a robust investigation [16][17][18][20][21][22][23][24].…”

Section: Discussionmentioning

confidence: 99%

“…De Boeck et al [19] found tumour progression to be highly influenced by bone marrow-derived mesenchymal stem cells releasing NRG1 in vitro and in vivo. Furthermore, two investigations indicated a potential role for predicting lymph node involvement and the occurrence of distant metastases [20][21][22]. Nevertheless, two cohorts of advanced CRC and one study of a cohort of CRC patients with distant metastases did not confirm effects on outcome [23][24][25].…”

Section: Introductionmentioning

confidence: 99%

“…This analysis was designed to confirm the prevalence and prognostic impact of HER2/neu, HER3 and NRG1 expression in a chemotherapy-based study cohort of 208 patients with mCRC (FIRE-1 trial) receiving either 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line therapy. To our knowledge, the FIRE-1 trial is the first randomized-controlled trial to investigate the impact of HER2/neu and HER3 receptor overexpression in relation to NRG1 expression [16][17][18][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer

Stahler¹,

Heinemann

Neumann

et al. 2017

Anti-Cancer Drugs

View full text Add to dashboard Cite

Our aim was to explore the impact of the HER2/neu, HER3 receptor as well as their ligands' neuregulin (NRG1) expression on the outcome of patients with metastatic colorectal cancer (mCRC). NRG1, HER2/neu and HER3 expression was evaluated in 208 patients with mCRC receiving 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as the first-line treatment. Biomarker expression was correlated with the outcome of patients. NRG1 (low: 192 vs. high: 16), HER2/neu (low: 201 vs. high: 7) and HER3 (low: 69 vs. high: 139) expressions were assessed in 208 patients. High versus low NRG1 expression significantly affected progression-free survival (PFS) [4.7 vs. 8.2 months, hazard ratio (HR): 2.45; 95% confidence interval (CI): 1.45-4.13; P=0.001], but not overall survival (OS) (15.5 vs. 20.7 months, HR: 1.33; 95% CI: 0.76-2.35; P=0.32). High versus low HER3 expression (PFS: 7.1 vs. 8.8 months, HR: 1.11; 95% CI: 0.82-1.50; P=0.50; OS: 19.8 vs. 21.1 months, HR: 0.95; 95% CI: 0.70-1.30; P=0.75) and high compared with low HER2/neu expression (PFS: 7.7 vs. 8.0 months, HR: 1.07; 95% CI: 0.71-1.60; P=0.75; OS: 16.6 vs. 21.1 months, HR: 1.13; 95% CI: 0.75-1.71; P=0.57) did not influence outcome. High NRG1 expression was associated with inferior PFS in the FIRE-1 trial. We did not detect a prognostic impact of HER2/neu and HER3 overexpression in mCRC. The frequency of overexpression was comparable with other studies.

show abstract

Research Progress on the Relationship Between Inflammation and Colorectal Cancer

Zhang

Qiao

2021

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Colorectal cancer (CRC), as one of the most prevalent types of cancer worldwide and the most common gastrointestinal malignant tumor, has become the third largest fatality rate of malignant tumor. [1][2][3] As people change their lifestyle in recent years, together with the environmental pollution influence factors, the incidence of CRC is on the rise in the world. CRC is easily misdiagnosed; those diagnosed in the early phase are less than 40% and for most of the patients at the time of definite diagnosis, the cancer has already metastasized. 4 Treatment with surgery is given priority, combined with radiotherapy and chemotherapy, but epidemiological data show that patients with CRC mortality are higher still. 5,6 In the middle of the nineteenth century, Virchow observed leukocyte infiltration in tumor tissues and first proposed the possible correlation between malignant tumors and inflammation. 7 With the deepening of such research, it has now been confirmed that chronic inflammation takes part in a tumor's start, proliferation, metastasis, aging, and apoptosis at various stages. Inflammation is also known as the seventh largest biological feature of malignant tumor. [7][8][9][10]

show abstract

HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver

Cited by 19 publications

References 24 publications

HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer

HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer

Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer

Research Progress on the Relationship Between Inflammation and Colorectal Cancer

Contact Info

Product

Resources

About